Hepatitis C News and Research

Latest Hepatitis C News and Research

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

The USPSTF agreed with the CDC that since most patients (75%) who are currently infected with hepatitis C were born between 1945 - 1965, and since risk-based screening has not been successful in identifying these individuals, that a one time age-based hepatitis C blood test was necessary.

29 Jul 2013

World Hepatitis Alliance calls for urgent action to address viral hepatitis

On World Hepatitis Day, the World Hepatitis Alliance has called for urgent attention to be given to recent figures showing that although viral hepatitis kills as many as HIV/AIDS, the great majority of countries have no programmes in place to tackle it.

29 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

Miriam researcher calls for new strategies to better manage, improve treatment for HCV infection

A Miriam Hospital researcher has joined forces with international colleagues to call for new strategies to better manage and improve assessment and treatment for hepatitis C (HCV) infection in individuals who inject drugs.

26 Jul 2013

Combination treatment can reduce hepatitis C infection in people who inject drugs

The burden of liver disease could be dramatically reduced by scaling up the combination of interventions for hepatitis C infection among people who inject drugs according to University of Bristol researchers. The findings, published today [24 July], form part of new global recommendations on treating the virus.

25 Jul 2013

Combination of 6 comprehensive measures to prevent spread of hepatitis C

UC San Francisco researchers are recommending a combination of six comprehensive measures to prevent the spread of hepatitis C, in an effort to address the more than 31,000 young people they estimate may be newly infected with the virus each year in the United States due to injection-drug use.

25 Jul 2013

WHO urges governments to act against five hepatitis viruses that cause severe liver infections

On World Hepatitis Day (28 July), the World Health Organization (WHO) is urging governments to act against the five hepatitis viruses that can cause severe liver infections and lead to 1.4 million deaths every year. Some of these hepatitis viruses, most notably types B and C, can also lead to chronic and debilitating illnesses such as liver cancer and cirrhosis, in addition to loss of income and high medical expenses for hundreds of millions of people worldwide.

24 Jul 2013

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Inovio Pharmaceuticals, Inc. announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.

24 Jul 2013

Researchers provide new model for studying drug targets and therapies for AIH

A gene mutation disrupts the activity of certain immune cells and causes the immune system to erroneously attack the liver, according to a new animal study from the Icahn School of Medicine at Mount Sinai.

24 Jul 2013

Inovio's electroporation technology enhances ability of DNA therapy to stimulate blood vessel growth

Inovio Pharmaceuticals, Inc. announced today that the use of its proprietary electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth, which may be beneficial for the treatment of critical limb ischemia and other forms of peripheral arterial disease.

18 Jul 2013

Researchers seek virus genes that allow animal hepatitis E strains infect humans

X.J. Meng, a University Distinguished Professor at Virginia Tech and a virologist at the Virginia-Maryland Regional College of Veterinary Medicine, has received a four-year, nearly $1.6 million grant from the National Institutes of Health to better understand the genetic elements that allow hepatitis E virus to transfer from animals to people.

17 Jul 2013

Researchers identify genes that allow animal hepatitis E virus strains to infect humans

16 Jul 2013

Sorrento Therapeutics, BGN partner to develop therapeutic antibodies for Hepatitis C Virus

Sorrento Therapeutics, Inc. and B.G. Negev Technologies and Applications Ltd., the technology transfer company of Ben-Gurion University of the Negev, have announced an option and license agreement to develop therapeutic products to treat Hepatitis C Virus.

10 Jul 2013

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Codex Alimentarius Commission approves new standards to protect consumers' health

The UN food standards body Codex Alimentarius has agreed on new standards to protect the health of consumers worldwide. These include standards on fruit, vegetables, fish and fishery products and animal feed.

9 Jul 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

State highlights: Docs prescribe narcotics too often, CDC chief says; Fla. hospices get close scrutiny; Calif. Medi-Cal provider rate bump delayed

The nation's top public health official on Tuesday sharply criticized the widespread treatment of aches and pains with narcotics, saying that doctors are prescribing such drugs too soon, too often and for too long -- putting patients at risk of addiction and overdose. Dr. Tom Frieden, director of the U.S. Centers for Disease Control and Prevention, said that doctors are relying on these powerful drugs to treat chronic pain when physical therapy, exercise and other remedies would be safer and in many cases more effective (Girion and Glover, 7/2).

4 Jul 2013

First Edition: July 3, 2013

Today's headlines detail the Obama administration announcement that it would delay the health law rule requiring businesses provide insurance to workers.

3 Jul 2013

UH and Case Western Reserve University to develop diagnostic tests to determine HIV drug resistance

Case Western Reserve University has signed an exclusive worldwide licensing agreement granting University Hospitals Case Medical Center rights to a series of diagnostic tests to determine drug resistance and co-receptor tropism in human immunodeficiency virus.

2 Jul 2013

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides, Inc. announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

1 Jul 2013

Hepatitis C News and Research

Latest Hepatitis C News and Research

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

World Hepatitis Alliance calls for urgent action to address viral hepatitis

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Miriam researcher calls for new strategies to better manage, improve treatment for HCV infection

Combination treatment can reduce hepatitis C infection in people who inject drugs

Combination of 6 comprehensive measures to prevent spread of hepatitis C

WHO urges governments to act against five hepatitis viruses that cause severe liver infections

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Researchers provide new model for studying drug targets and therapies for AIH

Inovio's electroporation technology enhances ability of DNA therapy to stimulate blood vessel growth

Researchers seek virus genes that allow animal hepatitis E strains infect humans

Researchers identify genes that allow animal hepatitis E virus strains to infect humans

Sorrento Therapeutics, BGN partner to develop therapeutic antibodies for Hepatitis C Virus

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Codex Alimentarius Commission approves new standards to protect consumers' health

Soligenix announces personalized medicine collaboration with SciClone

State highlights: Docs prescribe narcotics too often, CDC chief says; Fla. hospices get close scrutiny; Calif. Medi-Cal provider rate bump delayed

First Edition: July 3, 2013

UH and Case Western Reserve University to develop diagnostic tests to determine HIV drug resistance

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in